American biotechnology company Moderna’s coronavirus vaccine candidate mRNA-1273 gave protection against the virus in a trial on 16 monkeys, the company announced.
Two injections of the vaccine protected the primates against heavy exposure to the virus at two different levels of dosage, Moderna said.
No evidence of vaccine-associated enhanced disease (VAERD) was observed, it added.
US-based Moderna has started a US government-backed late-stage trial evaluating its COVID-19 vaccine candidate, mRNA-1273, in about 30,000 adults who do not have the respiratory illness caused by the new coronavirus.
The main goal of the study will be prevention of the symptomatic COVID-19 disease, the company added.
Moderna received $483 million from US federal agency in April.
We just announced the publication of a nonhuman primate preclinical viral challenge study of mRNA-1273 in @NEJM.
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger
RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients
today announced a preclinical study evaluating mRNA-1273
its vaccine candidate against COVID-19, was published in The New England Journal of Medicine.
The study showed a two-dose vaccination schedule of mRNA-1273 led to a robust immune response and protection against SARS-CoV-2 infection
in the upper and lower airways in non-human primates, without evidence of vaccine-associated enhanced respiratory disease (VAERD).July 28, 2020